Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 23Phase 1/2 5Phase 1 4Phase 2/3 3Phase 4 1

Status

Completed 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 4Lymphoid 1

Conditions

Melanoma 4Neoplasms 1Neoplasm Metastasis 1Hodgkin Disease 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Dacarbazine × Clear all
NCT02979522 2025-11-10

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Takeda

Phase 1/2 Active not recruiting
59 enrolled 63 charts
Lymphoid

Hodgkin Disease

NCT02076646 2022-04-14

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Philogen S.p.A.

Phase 1/2 Unknown
96 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT01133977 2016-10-10

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Eisai Inc.

Phase 1/2 Completed
97 enrolled 8 charts
Dermatologic

Melanoma

NCT00246012 2013-08-19

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Centocor, Inc.

Phase 1/2 Completed
144 enrolled 34 charts
Dermatologic

Melanoma, Neoplasms

NCT00327600 2010-09-15

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

AmpliMed Corporation

Phase 1/2 Completed
68 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡